Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo,Coraline Dubot,Domenica Lorusso,M Valeria Caceres,Kosei Hasegawa,Ronnie Shapira-Frommer,Krishnansu S. Tewari,Pamela Salman,Edwin Hoyos Usta,Eduardo Yáñez,Mahmut Gumus,Mivael Olivera Hurtado de Mendoza,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Sarper Toker,Kan Li,Stephen Michael Keefe,Bradley J. Monk,Keynote Investigators

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

2021

Abstract Background Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the rela...

Keywords:

Cervical cancer
Metastatic cervical cancer
Pembrolizumab
Oncology
Chemotherapy
programmed death
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations